Compugen Ltd.
NASDAQ:CGENBiotechnology
+$0.01 today
- Market cap
- $185.66M
- Beta
- 2.74
- P/E (TTM)
- 5.4
- EPS (TTM)
- $0.37
Volume 0.15M
Average 0.48M
CGEN Net Income
Bottom-line profit after all expenses, interest, and taxes.
Compugen Ltd.NASDAQ: CGEN
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$7.67M, compared with -$7.18M a year earlier. Trailing-twelve-month net income was $34.86M.
Context
- Net income amounted to 48.6% of revenue in FY2025, down 2.5 pp from a year earlier.
- Net income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$23.7M (-167.1%) for the fiscal year ending Dec 2026, a slowdown from the +348.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$7.67M-113.5% QoQ
- Last fiscal yearDec 2025
- $35.34M+348.4% YoY
- LTMMar 2026
- $34.86M+346.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -6.8% | -3.3% | +3.5 pp |
| 1 year | +348.4% | -167.1% | -515.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- 35.34M USD
- Year-over-year change
- +348.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 35.34M | +348.4% |
| FY2024 | 2024-12-31 | (14.23M) | +24.1% |
| FY2023 | 2023-12-31 | (18.75M) | +44.3% |
| FY2022 | 2022-12-31 | (33.69M) | +1.5% |
| FY2021 | 2021-12-31 | (34.2M) | — |
Net Income vs competitors
How CGEN compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +346.4% is the highest of 9, against a peer median of -14.6%.
- Net income amounts to 48.0% of revenue for CGEN, versus a peer median of 1764.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $34.86M USD | +346.4% | — | 48.0% | |
| LTM Mar 2026 | -$27.16M USD | -34.7% | — | — | |
| LTM Mar 2026 | -$29.44M USD | +1.2% | — | 929.1% | |
| LTM Mar 2026 | -$44.76M USD | +8.4% | — | 8526.1% | |
| FY2025 | -€49.18M EUR | +0.6% | — | 1764.5% | |
| LTM Mar 2026 | -$68.36M USD | -31.7% | — | 3832.0% | |
| LTM Mar 2026 | -CHF 72.06M CHF | -17.4% | — | — | |
| LTM Mar 2026 | -$84.53M USD | -68.1% | — | — | |
| LTM Mar 2026 | -$147.39M USD | -11.7% | — | 839.5% | |
| Peer median (excluding CGEN) | — | -14.6% | — | 1764.5% | |
Competitors are the stored peer set for CGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6M | 7.5M | 33.46M | 27.86M | 72.76M |
| Cost of Revenue | 680K | 975K | 2M | 7.93M | 9.25M |
| Gross Profit | 5.32M | 6.53M | 31.46M | 19.93M | 63.51M |
| Gross Margin | 88.7% | 87.0% | 94.0% | 71.5% | 87.3% |
| Research & Development | 28.69M | 30.65M | 34.47M | 24.81M | 22.76M |
| Selling, General & Admin | 11.7M | 11.25M | 9.98M | 10.02M | 9.43M |
| Operating Expenses | 40.39M | 41.9M | 44.45M | 34.83M | 32.19M |
| Depreciation & Amortization | 461K | 482K | 476K | 486K | 475K |
| EBITDA | (33.72M) | (33.13M) | (9.28M) | (9.19M) | 35.87M |
| EBITDA Margin | -562.0% | -441.7% | -27.7% | -33.0% | 49.3% |
| Operating Income | (35.07M) | (35.37M) | (12.99M) | (14.89M) | 31.33M |
| Operating Margin | -584.6% | -471.7% | -38.8% | -53.4% | 43.1% |
| Interest Income | 894K | 1.44M | 3.24M | 5.24M | 4.41M |
| Interest Expense | 25K | 27K | 31K | 34K | 0 |
| Other Income / Expenses | 871K | 1.74M | 3.21M | 5.18M | 4.07M |
| Income Before Tax | (34.2M) | (33.64M) | (9.78M) | (9.71M) | 35.4M |
| Pre-Tax Margin | -570.0% | -448.5% | -29.2% | -34.8% | 48.6% |
| Income Tax Expense | 0 | 58K | 8.97M | 4.52M | 54K |
| Net Income | (34.2M) | (33.69M) | (18.75M) | (14.23M) | 35.34M |
| Net Margin | -570.0% | -449.3% | -56.1% | -51.1% | 48.6% |
| EPS (Basic) | (0.41) | (0.39) | (0.21) | (0.16) | 0.38 |
| EPS (Diluted) | (0.41) | (0.39) | (0.21) | (0.16) | 0.38 |
| Weighted Avg Shares | 84.2M | 86.56M | 87.63M | 89.53M | 93.43M |
| Weighted Avg Shares (Diluted) | 84.2M | 86.56M | 87.63M | 89.53M | 93.82M |
Compugen Ltd.
NASDAQ:CGEN
Intrinsic Alpha fair value
Locked
Current Price
$1.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.